Joyce F. Liu

Also affiliated with Duke University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 25 papers. Top paper: “Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial”.

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.02011

N/A

2.6DataRank · unranked

88 citations

Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher +16 more

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Nature Communications(2021)10.1038/s41467-021-25904-w

N/A

1.9DataRank · unranked

69 citations

Alexandre André Balieiro Anastácio da Costa, D. Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson +14 more

A single-cell landscape of high-grade serous ovarian cancer

Nature Medicine(2020)10.1038/s41591-020-0926-0

N/A

0.938DataRank · unranked

518 citations

Itay Tirosh, Elizabeth H. Stover, Isaac Wakiro, Michael S. Cuoco, Idan Alter +30 more

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline

Journal of Clinical Oncology(2020)10.1200/jco.19.02960

N/A

0.894DataRank · unranked

387 citations

Barbara M. Norquist, Christina Lacchetti, Deborah K. Armstrong, Rachel N. Grisham, Paul J. Goodfellow +7 more

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-005627

N/A

0.683DataRank · unranked

94 citations

Qiwei Wang, Antons Martincuks, Michael J. Kearns, Tao Jiang, Ziying Lin +13 more

Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity

Cancer Research(2024)10.1158/0008-5472.can-23-4007

N/A

0.679DataRank · unranked

24 citations

Ozge Somuncu, Ramya Ravindranathan, Sirisha Mukkavalli, David B. Martignetti, Huy Nguyen +11 more

EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5505

N/A

0.665DataRank · unranked

83 citations

Robert L. Coleman, Bryan Fellman, Ying Yuan, Anil K. Sood, Pamela T. Soliman +15 more

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study

Journal of Clinical Oncology(2024)10.1200/jco.23.02076

N/A

0.644DataRank · unranked

20 citations

Ronald J. Buckanovich, Michael W. Sill, Robert S. Mannel, Joan L. Walker, Paul DiSilvestro +13 more

Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53 -Mutant Cancers

Cancer Research(2022)10.1158/0008-5472.can-22-1124

N/A

0.624DataRank · unranked

63 citations

Arindam Bose, Wei-Chih Tsai, Carter Grochala, Huy Nguyen, Jia Zhou +8 more

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6003

N/A

0.606DataRank · unranked

56 citations

Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher +15 more

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3135

N/A

0.546DataRank · unranked

37 citations

T. Khanh, Jeong Eun Kim, James M. Cleary, Aparna R. Parikh, Oladapo Yeku +26 more

Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2834

N/A

0.538DataRank · unranked

35 citations

Nabihah Tayob, Livius Penter, MacLean Sellars, Anna Tarren, Vipheaviny Chea +19 more

A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5501

N/A

0.512DataRank · unranked

9 citations

Ronald J. Buckanovich, Michael W. Sill, Robert S. Mannel, Joan L. Walker, Paul DiSilvestro +13 more

PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2413954121

N/A

0.510DataRank · unranked

29 citations

Ozge Somuncu, Alexandre André Balieiro Anastácio da Costa, Sirisha Mukkavalli, Benjamin P. Lamarre, Huy Nguyen +8 more

Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype

Journal of Clinical Investigation(2022)10.1172/jci155931

N/A

0.483DataRank · unranked

24 citations

Siyu Sun, Micayla N. Flores, Emily Berzolla, Eunae You, Ildiko E. Phillips +22 more

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.100974

N/A

0.416DataRank · unranked

15 citations

Niya Xiong, Andrea P. Myers, Nabihah Tayob, Victoria Engvold, Madeline Polak +14 more

Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X L degradation to overcome cancer chemoresistance

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.06.24.661170

N/A

0.373DataRank · unranked

11 citations

Adam Presser, Lissah Johnson, Yusuke Matoba, Brendan Shay, Weiyi Xu +19 more

In vivo synergism between PARP-inhibitor olaparib and HSP90-inhibitor AT13387 in high grade serous ovarian cancer patient derived xenografts.

Journal of Clinical Oncology(2016)10.1200/jco.2016.34.15_suppl.e17045

N/A

0.312DataRank · unranked

7 citations

Sangeetha Palakurthi, Qing Zeng, Shan Zhou, Joyce F. Liu, Elena Ivanova +6 more

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5512

N/A

0.292DataRank · unranked

6 citations

Elizabeth Katherine Lee, Su–Chun Cheng, Alexandre André Balieiro Anastácio da Costa, Andrea E. Wahner Hendrickson, D. Gulhan +14 more

910 STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0910

N/A

0.269DataRank · unranked

5 citations

Qiwei Wang, Antons Martincuks, Michael Kearns, Tao Jiang, Ziying Lin +12 more

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Gynecologic Oncology Reports(2020)10.1016/j.gore.2020.100546

N/A

0DataRank · unranked

18 citations

Zhenying Tan‐Wasielewski, Carol Aghajanian, Robert L. Coleman, Jennifer Curtis, Michelle S. Hirsch +6 more

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

Journal of Clinical Oncology(2020)10.1200/jco.20.01924

N/A

0DataRank · unranked

315 citations

Christina Lacchetti, Annie Ellis, Kathleen Maxian, Susana Banerjee, Michael A. Bookman +11 more

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3877

N/A

0DataRank · unranked

8 citations

Austin Miller, Peter G. Rose, Mariam AlHilli, Christina Washington, Veena S. John +15 more

Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions

Cancers(2021)10.3390/cancers13092195

N/A

0DataRank · unranked

2 citations

Joyce F. Liu, Nikolas Kesten, Kin-Hoe Chow, Aniket Shetty, Ruiyang He +13 more

Impact of liposomal bupivacaine transversus abdominal pain blocks compared to ropivacaine incision site infiltration after discharge: An observational prospective cohort quality improvement study

European Journal of Obstetrics & Gynecology and Reproductive Biology(2025)10.1016/j.ejogrb.2025.114736

N/A

0DataRank · unranked

0 citations

Melissa Greene, Tracy Truong, Chun Xu, Joyce F. Liu, A.H. Song +4 more